

**Statements of Principles with factors relating to mefloquine or tafenoquine**

<b>Condition</b>	<b>Instrument Nos.</b>	<b>Factor and terminology related to mefloquine or tafenoquine</b>
acquired cataract	87 of 2016	taking an antimalarial agent for a consecutive period of at least 6 months before the clinical onset/worsening of acquired cataract; <b>mefloquine</b> and <b>tafenoquine</b> can be classed as "an antimalarial agent"
anxiety disorder	102 & 103 of 2014, amended by 99 & 100 of 2016	for substance/medication-induced anxiety disorder only, taking a drug or a drug from a class of drugs from the specified list of drugs, within the two days before the clinical onset of anxiety disorder; or taking a drug or a drug from a class of drugs from the specified list of drugs, within the two days before the clinical worsening of anxiety disorder; "specified list of drugs" includes <b>mefloquine</b>
bipolar disorder	53 & 54 of 2018	for substance/medication-induced bipolar and related disorder only: taking a drug, or a drug from a class of drugs, from the specified list of drugs, within the 14 days before the clinical onset of bipolar disorder; "specified list of drugs" includes <b>mefloquine</b>
depressive disorder	83 & 84 of 2015	for substance/medication-induced depressive disorder only, taking a drug or a drug from a class of drugs from the specified list of drugs, within the 30 days before the clinical onset of depressive disorder; taking a drug or a drug from a class of drugs from the specified list of drugs, within the 30 days before the clinical worsening of depressive disorder; "specified list of drugs" includes <b>mefloquine</b>
epileptic seizure	77 & 78 of 2013	being treated with a drug or a drug from a class of drugs from the specified list, within the 24 hours before the clinical onset of an epileptic seizure, and where multiple seizures occur, the first seizure occurred within the 24 hours of being treated with the drug or the drug from the class of drugs; "a drug or a drug from a class of drugs from the specified list" includes antimalarials and <b>mefloquine</b> and <b>tafenoquine</b> are antimalarials
heart block	1 & 2 of 2014	being treated with a drug or a drug from a class of drugs from the specified list, where that drug cannot be ceased or substituted, at the time of the clinical onset/worsening of heart block; "a drug or a drug from a class of drugs from the specified list" includes <b>mefloquine</b>
methaemoglobinaemia	47 & 48 of 2010	taking or being treated with a drug that causes oxidation of haemoglobin, within the two days before the clinical onset/worsening of methaemoglobinaemia; <b>tafenoquine</b> is a drug that causes oxidation of haemoglobin
myasthenia gravis	75 & 76 of 2015	being treated with a drug from Specified List of Drugs No. 3 at the time of the clinical worsening of myasthenia gravis; "Specified List of Drugs No. 3" includes <b>mefloquine</b>

peripheral neuropathy	74 of 2014	being treated with a drug or a drug from a class of drugs from Specified List 1, for a condition for which the drug cannot be ceased or substituted, at the time of the clinical onset of peripheral neuropathy; "a drug or a drug from a class of drugs from Specified List 1" includes <b>mefloquine</b>
psoriasis	31 & 32 of 2012	for a first episode of psoriasis only, being treated with a drug or a drug from a class of drugs in the specified list for at least the seven days before the clinical onset of psoriasis; being treated with a drug or a drug from a class of drugs in the specified list for at least the seven days before the clinical worsening of psoriasis; "a drug or a drug from a class of drugs in the specified list" includes synthetic antimalarial drugs and <b>mefloquine</b> and <b>tafenoquine</b> are synthetic antimalarial drugs
sensorineural hearing loss	5 & 6 of 2011	undergoing a course of treatment with a drug or a drug from a class of drugs from the specified list within the one year before the clinical onset/worsening of sensorineural hearing loss; "a drug or a drug from a class of drugs from the specified list" includes quinine derivatives and <b>mefloquine</b> and <b>tafenoquine</b> are quinine derivatives
schizophrenia	83 & 84 of 2016	taking a drug from the class of drugs from Specified List 2 of drugs within the 30 days before the clinical worsening of schizophrenia; "Specified List 2 of drugs" includes <b>mefloquine</b>
suicide and attempted suicide	65 & 66 of 2016	taking <b>mefloquine</b> within the six months (balance of probabilities SoP three months) before the suicide or the attempted suicide;
tinnitus	33 & 34 of 2012	taking a drug or a drug from a class of drugs from the specified list within the one month before the clinical onset/worsening of tinnitus; "a drug or a drug from a class of drugs from the specified list" includes quinine derivatives and <b>mefloquine</b> and <b>tafenoquine</b> are quinine derivatives
toxic retinopathy	19 of 2018	being treated with a quinoline-based drug as specified, before the clinical onset of toxic retinopathy;  "being treated with a quinoline-based drug as specified" means: (a) taking daily chloroquine for a continuous period of at least six months; or (b) taking a cumulative dose of chloroquine of at least 100 grams; or (c) taking daily hydroxychloroquine for a continuous period of at least five years; or (d) taking a cumulative dose of hydroxychloroquine of at least 400 grams; or (e) taking daily quinacrine (mepacrine or Atebrin) for a continuous period of at least six months; or (f) taking a cumulative dose of quinacrine of at least 20 grams; or (g) taking a cumulative dose of at least 1000 mg of <b>mefloquine</b> within a 30 day period.
trigeminal neuropathy	79 of 2015	being treated with a drug from the specified list of drugs, for a continuous period of at least seven days, within the three months before the clinical onset/worsening of trigeminal neuropathy; "specified list of drugs" includes <b>mefloquine</b>